Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neuro-Ophthalmology Oculoplastics Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login

The Art & Science of Managing Diabetic Eye Disease

By: Allen C. Ho, MD, FACS (Chair); Maria H. Berrocal, MD; Mrinali Gupta, MD; M. Ali Khan, MD; Raj K. Maturi, MD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

Content Source
This continuing medical education (CME) activity captures content from a virtual roundtable discussion.

Activity Description
A group of retina specialists from across the country discusses the benefits of consistent treatment for diabetic eye disease and how to improve patient adherence to follow-up visits, as well as expand communication with the patient’s care team in order to improve visual outcomes with currently available therapies.

Target Audience
This certified CME activity is designed for retina specialists.

Expiration Date: Saturday, December 31, 2022
Release Date: December 31, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss the benefits of consistent anti-VEGF treatment.
  • Explain why patients with diabetic retinopathy (DR) and diabetic macular edema (DME) are so often lost to follow-up.
  • Execute patient education plans on the importance of frequent DME treatment to improve treatment and exam compliance.
  • Apply best practices and strategies in a cross-disciplinary approach to diabetes management to better manage patients.

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement[s] for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Allen C. Ho, MD, FACS (Chair)

Program Chair
Director, Retina Research
Wills Eye Hospital 
Philadelphia, PA 

Maria H. Berrocal, MD

CEO
Drs. Berrocal & Associates
Assistant Professor
University of Puerto Rico School of Medicine
San Juan, PR 

Mrinali Gupta, MD

Physician
Retina Associates of Orange County
Laguna Hills, CA 

M. Ali Khan, MD

Physician
Wills Eye Hospital
Mid-Atlantic Retina
Philadelphia, PA 

Raj K. Maturi, MD

Associate Professor of Ophthalmology
Indiana University
Midwest Eye Institute 
Indianapolis, IN

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Allen C. Ho, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Aerie Pharmaceuticals, AGTC, Alcon Vision, Aldeyra, Allergan, Apellis, Asclepix, Beaver-Visitec International, Chengdu Kanghong Biotechnology, Clearside, Genentech, Gyroscope Therapeutics, Iveric/Ophthotech, Janssen/Johnson & Johnson Vision, MeiraGTX, Lineage, Notal Vision, Ocular Therapeutix, ONL, Regeneron, and Regenxbio. Grant/Research Support: Adverum, Aerie Pharmaceuticals, AGTC, Alcon Vision, Aldeyra, Allergan, Apellis, Asclepix, Chengdu Kanghong Biotechnology, Genentech, Graybug, Gyroscope Therapeutics, Iveric/Ophthotech, Janssen/Johnson & Johnson Vision, Lineage, Lumithera, and Meira GTX, National Eye Institute, Notal Vision, Novartis, ProQR, Regeneron, and Regenxbio. Other Support: Covalent Medical.

Maria H. Berrocal, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon and Allergan. Speaker’s Bureau: Alcon, Allergan, and Roche.

Mrinali Gupta, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, and Carl Zeiss Meditec. Intellectual property: Sonder Research X. 

M. Ali Khan, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Apellis, and Genentech. Grant/Research Support: Regeneron. 

Raj K. Maturi, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aiviva, Allegenesys, DORC International BV, Eli Lilly, ForwardVue, Neurotech, and Oxurion. Grant/Research Support: Aerpio, Allergan/AbbVie, Allegro Ophthalmics, Boehringer Ingelheim Pharma, Gyroscope Therapeutics, Glaxosmithkline, Graybug, Kalvista, Oxurion NV, Roche/Genentech, Samsung Bioepis, and Santen. 

The Evolve staff and planners have no financial relationships with commercial interests. 

Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Retina Today, or Regeneron.

Begin Course